Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

Wakamoto Pharmaceutical is a pioneering company for self-medication with the launch of a nutrient-rich, gastrointestinal remedy. In recent years, the environment surrounding the pharmaceutical industry has been undergoing major changes. In particular, the baby boomer generation will reach age 75 or over and enter the senior citizen demographic in 2025, and Japan will face increasingly lower birth rates and a more aged society. Meanwhile, sustained systemic reform efforts are advancing for the National Health Insurance system, while fundamental reform of the drug pricing system progresses in order to reduce the medical expense burden on the nation. These shifts are occurring with unprecedented speed.

Senju USA is a pharmaceutical company in the field of ophthalmology.

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Ouchi Shinko Chemical Industrial is one of the leading manufacturer of organic rubber chemicals, and polymer stabilizers.

Beijing Keyuan Chuangxin Technology Co., Ltd., established on 2012-07-20, Business scope includes technology development,Technical Services,technology transfer(human stem cells,Except for the development and application of genetic diagnosis and treatment technology);Sales of chemical products(Free of Hazardous Chemicals),Instrumentation,laboratory equipment,daily necessities,building materials,decorative material,Wujinjiaodian(E-bike not included),electronic product,Equipment,plastic products,stationery,sporting goods(without crossbow);Economic and Trade Consulting;Conference Services;Undertake the exhibition;Organize cultural and artistic exchange activities.(Market entities independently choose business projects in accordance with the law,Carry out business activities;the enterprise2021year9moon26Currently a domestic enterprise,At2021year9moon26Changed to a foreign-funded enterprise;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Pierre Fabre Dermatologie SAS manufactures and markets products for skin diseases. It manages dermatological skin diseases such as acne. The company was founded in September 30, 1996 and is headquartered in Boulogne-Billancourt, France.

TOA Pharmaceuticals Co., Ltd. is a Japanese company located in Toyama that manufactures and distributes drugs. It was founded in 1940.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

Teijin Pharma Ltd. engages in the development, production, sales, and marketing of pharmaceuticals, and medical devices and supplies. The company operates in pharmaceutical and home healthcare businesses, focusing on bone and joint diseases, respiratory diseases, and cardiovascular and metabolic diseases. The company was founded in 2002 and is headquartered in Tokyo, Japan.

Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ.

NicOx is a biopharmaceutical company, engages in the development and commercialization of nitric oxide (NO)-donating drugs primarily for inflammation and cardio-metabolic diseases. The company's primary products candidates include Naproxcinod, a Phase III product candidate for the treatment of osteoarthritis; and NCX 6560, a NO-donating compound for the treatment of cardiovascular diseases, which is in phase I clinical trials. Its product portfolio comprise PF-03187207 for the treatment of glaucoma, TPI 1020 for the treatment of respiratory disorders, and NCX 1510 for allergic rhinitis, which are in Phase II clinical trials; and NO-donating antihypertensives, which is in phase I clinical trials for the treatment of hypertension. The company's product pipeline also include NCX 1047, which is in preclinical stage of development for treating a range of skin disorders, such as atopic dermatitis, psoriasis, and seborrheic dermatitis; and NO-donors for diabetic retinopathy, cardiometabolic, inflammation, and pain. It has research and co-development agreement with Orexo AB to identify and develop compounds for the treatment of airway diseases; license and development agreement with TOPIGEN Pharmaceuticals Inc. The company also has agreements with Grupo Ferrer Internacional SA for the research, development, and marketing of NO-donating anti-inflammatory drugs for the treatment of dermatological diseases; Pfizer Inc to identify nitric oxide-donating compounds for diabetic retinopathy; and Merck & Co., for the development of new antihypertensive drugs using NicOx' nitric oxide-donating technology. NicOx S.A. was founded in 1996 and is headquartered in Sophia Antipolis, France.

Merz Pharma GmbH & Co. KGaA is an innovative and international healthcare company with its own research and development department. It focuses on drugs for the treatment of illness in the fields of neurology and psychiatry. The company is bundling the activities of its subsidiaries Merz Pharmaceuticals, Merz Consumer Care, Merz Dental, and Merz Hygiene, with products ranging from prescription drugs and OTC products for health and wellness, materials for dentists and dental technicians to hygienic products for medical disinfection and cleaning.\nThe units of Merz Group Services, the fith Merz subsidiary, include Human Resources, Supply Chain/Purchasing, Information Technology (IT), Technical Operations and Finances/Controlling.

Reliant Pharmaceuticals provides cardiovascular pharmaceutical products. It is engaged in the sale and marketing of these products. Its product portfolio includes Axid, a nizatidin; InnoPran XL and DynaCirc CR for the treatment of hypertension; Omacor to reduce high triglycerides; and Rythmol SR. It provides products for the treatment of elevated cholesterol and triglycerides, acid reflux disease, and prevention of coronary complications in patients with coronary heart disease. It distributes its products to physicians engaged in primary care, cardiovascular, and specialized medical areas. Reliant Pharmaceuticals was established in 1999, headquartered in Liberty Corner, New Jersey.

Ningbo Toppu Biotechnology Co., Ltd., established on 2014-07-09, The scope of business includes the production of chromatographic instruments;Chromatography Packing,Chromatographic instrument,High Performance Membrane Materials,biological reagent,Research and development of chemical reagents,Sales;Research and Development of Experimental Instruments,Sales;Sales of Class I Medical Devices;Chromatography instrument analysis test service;Technical service and transfer.

R-Tech Ueno Ltd. engages in the research and development, manufacture and sale of pharmaceutical products. It operates through the following business divisions: New Pharmaceutical Research and Development, Pharmaceutical Manufacture and Sale, and Pharmaceutical Development Support and Contract Manufacturing Services. The New Pharmaceutical Research and Development business provides development for unmet medical needs area, orphan drug area, and anti-aging area. The Pharmaceutical Manufacture and Sale business handles the manufacture and sale of Rescula Eye Drops for glaucoma and ocular hypertension. The Pharmaceutical Development Support and Contract Manufacturing Services business covers the manufacture and sale of AMITIZA capsules for chronic idiopathic constipation. It also accepts contract manufacturing of eye drops, liquid drugs and liquid-filled hard capsules. The company was founded by Ryuji Ueno and Sachiko Kuno in September 1989 and is headquartered in Tokyo, Japan.

Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert in 1950 and headquartered in Irvine, CA.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.